Anzeige
Mehr »
Login
Dienstag, 15.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Diese Fusion könnte der Katalysator sein, den Anleger brauchen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Medien-Archiv vom 23.05.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
23.05.Cereno Scientific AB: Cereno Scientific publishes the interim report for Q1 2024 ( January 1-March 31)4The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q1 2024 (January 1-March 31). Summary of the interim report for Q1 2024 (January 1-March 31) Cereno...
► Artikel lesen
23.05.Redwood Pharma AB: Redwood Pharma provides an update on the company's future48Stockholm, 23 May 2024. Redwood Pharma AB (publ) announces today that the company is evaluating potential solutions to address its strained financial situation. This is in light of the fact that the...
► Artikel lesen
23.05.Fragbite Group AB: Fragbite Group declares subsidiary Fall Damage Studio bankrupt63The board of directors of Fragbite Group AB publ ("Fragbite Group" or the "Company") has today, on 23 May 2024, resolved to declare bankruptcy for its subsidiary Fall Damage Studio AB ("Fall Damage")....
► Artikel lesen
23.05.Fragbite Group AB: Marcus Teilman resigns from the position of CEO at his own request70Today, CEO Marcus Teilman informed the Board of Directors of Fragbite Group AB (publ) ("Fragbite Group" or the "Company") that he wishes to terminate his employment. The Board has accepted his request...
► Artikel lesen
23.05.Franklin Metaverse UCITS ETF: Namensänderung78Sie erhalten diese Mitteilung, da Sie Anteile am Franklin Metaverse UCITS ETF (der "Teilfonds") besitzen, einem Teilfonds des Franklin Templeton ICAV (das "ICAV"). Dieses Dokument ist wichtig und...
► Artikel lesen
23.05.Scandion Oncology A/S: Scandion Oncology Announces The Final Terms Of The Rights Issue195On 19 April 2024, the board of directors of Scandion Oncology ("Scandion" or the "Company") resolved on the intention, subject to authorizations by the annual general meeting of the Company, to carry...
► Artikel lesen
23.05.Nordrest Holding AB: Nordrest's offering was substantially oversubscribed - trading in the share on Nasdaq First North Growth Market commences today337THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHES, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA...
► Artikel lesen
23.05.X-FAB and Soitec team to offer SmartSiC at Lubbock plant in Texas24
23.05.Navitas highlights power semis for AI, EV, industrial, solar and energy storage at PCIM8
23.05.Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer?95BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety...
► Artikel lesen
23.05.ACCIONA, S.A.: Q1 2024 Trading Statement (January - March)210EXECUTIVE SUMMARY ACCIONA has begun 2024 progressing well towards its objective of installing 1.7 GW of new renewable energy capacity for the second year in a row, and achieving strong performance...
► Artikel lesen
23.05.Bowhead Specialty Announces Pricing of Upsized Initial Public Offering114NEW YORK--(BUSINESS WIRE)--Bowhead Specialty Holdings Inc. (the "Company", "Bowhead Specialty", "we" or "our") announced today the pricing of its upsized initial public offering of 7,529,412 shares...
► Artikel lesen
23.05.Millicom International Cellular S.A.: Millicom (Tigo) comments on shareholder communication359Millicom (Tigo) comments on shareholder communication Luxembourg, May 23, 2024 - The Board of Directors of Millicom International Cellular S.A. ("Millicom") confirms that it received today a non-binding...
► Artikel lesen
23.05.Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide257Company announcement - No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean...
► Artikel lesen
23.05.Pepco Group N.V.: Interim results for six months ended 31 March 2024166Strong H1 profit growth with tangible strategic progress Pepco Group, the fast-growing pan-European variety discount retailer, today reports interim results for the six-month period ended 31 March...
► Artikel lesen
23.05.Coherus BioSciences, Inc.: Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting213CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells...
► Artikel lesen
23.05.Premier Health of America Inc.: Premier Health Reports 2024 Second Quarter Results407MONTRÉAL, May 23, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the "Corporation"), a leading Canadian Healthtech company, announces it has filed its Unaudited Quarterly Consolidated...
► Artikel lesen
23.05.Elicio Therapeutics, Inc.: Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting168ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T...
► Artikel lesen
23.05.Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq153New York, NY, May 23, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ: FRES) ("Fresh2" or the "Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry...
► Artikel lesen
23.05.Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101280- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast...
► Artikel lesen
Seite:  Weiter >>